Healthcare Sales & Marketing Network News: IMPACT study

Searching News Database: IMPACT study

HSMN NewsFeed - 21 Aug 2024
PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments
Diagnostics Oncology Venture Capital

HSMN NewsFeed - 7 Aug 2020
Haemonetics Clinical Study Results On A New, Personalized Approach To Plasma Collection To Be Presented At 2020 AABB Annual Meeting
Devices

HSMN NewsFeed - 6 Mar 2020
PreludeDx Announces New Response Type Biosignature Data at the 37th Annual Miami Breast Cancer Conference
Diagnostics Oncology

HSMN NewsFeed - 9 Dec 2016
Genomic Health Announces Results from Multiple Oncotype DX(R) Studies, Reinforcing its Impact in Delivering Precision Medicine to Breast Cancer Patients Around the World
Diagnostics Personalized Medicine Oncology

HSMN NewsFeed - 21 Jun 2016
Theravance Biopharma Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva
Biopharmaceuticals

HSMN NewsFeed - 1 Oct 2013
Genomic Health Announces Presentation of Oncotype DX(R) Studies Reinforcing Value of Tests in Guiding Treatment for Multiple Cancers
Diagnostics Oncology

HSMN NewsFeed - 17 Sep 2013
Dendreon Announces Marketing Authorization for PROVENGE(R) in the European Union
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Apr 2012
BIOTRONIK REPLACE Study Establishes New Benchmarks for CIED Replacement
Devices Cardiology

HSMN NewsFeed - 20 Jan 2012
Genzyme and Veracyte Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients
Diagnostics Endocrinology Oncology Personalized Medicine

HSMN NewsFeed - 28 Apr 2009
Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Apr 2009
PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 13 Feb 2009
IMPACT Study Demonstrates That Longer Prophylactic Therapy With Valcyte(R) (Valganciclovir Hydrochloride Tablets) Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients
Biopharmaceuticals

HSMN NewsFeed - 26 Sep 2008
The New BIOTRONIK Home Monitoring(R) Approved in Europe
Devices Cardiology Monitoring Regulatory

HSMN NewsFeed - 12 Mar 2008
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Nov 2007
HealthTrust Purchasing Group and Bracco Diagnostics Inc. Sign Three-Year Agreement for X-Ray Contrast Media
Biopharmaceuticals Radiology Group Purchasing

HSMN NewsFeed - 31 May 2007
Dendreon Announces FDA Confirms Data Required for Provenge(R) Licensure
Biopharmaceuticals FDA

HSMN NewsFeed - 9 May 2007
Dendreon Receives Complete Response Letter From FDA for Provenge(R) Biologics License Application
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 31 Oct 2006
The Latest Head-to-Head Clinical Study Comparing the Risk of CIN between Two Contrast Agents Used in CE-MDCT Examinations Was Published in Investigative Radiology
Biopharmaceuticals Radiology

Return to NewsFeed

Additional items found! 5

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 5 additional stories matching:
IMPACT study
(Password required)

FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.

RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!